SUNNYVALE, Calif., Jan. 10 /PRNewswire-FirstCall/ -- Molecular Devices Corporation today announced the launch of SoftMax Pro 5 data acquisition and analysis software for its extensive line of microplate readers. The new software is available in two editions: SoftMax Pro 5 for use in research and academic laboratories, and SoftMax Pro 5 GxP with FDA 21 CFR Part 11 compliance features for the pharmaceutical and biotechnology industries. Both software versions are compatible for the first time with Mac OS X and also continue to support Microsoft Windows operating systems.

Ciprofloxacin concentration in the supernatant was quantified via UV/Vis absorbance measures taken at 246nm (SoftMax Pro 5, Molecular Devices, Sunnyvale, CA), with background signal from blank MS subtracted from each measurement and regressed against the standard curve, validated for 1–10μg/ml. Download SoftMax® Pro 7.0 Microplate Data Acquisition & Analysis Software for Windows. Supported Windows Operating System: Version 7: Win 7, Win 8, Win 8.1, Win 10. Version 7.0 and below: Compatible with both 32-bit and 64-bit OS. Viewing this answer requires an authorized account. The information is below the horizontal line. A computer software program capable of implementing the calculations described below. Presently, the CVB Laboratories use SoftMax Pro (SMP) versions 6.2.1 or 6.3 on the Windows 7 platform; later versions of an SMP/operating system combination may be.

'The launch of SoftMax Pro 5 is a significant upgrade for our 23 microplate reader product lines,' said Jan Hughes, VP Marketing at Molecular Devices. 'We solicited input from researchers from over 50 leading pharmaceutical and biotechnology companies to address research, validation and IT requirements, and their feedback is evident in the new software capabilities.' He further stated, 'We're also very excited about bringing SoftMax Pro 5 to Mac OS X to support our users in this area.'

SoftMax Pro 5 introduces 5-parameter logistic curve fit and parallel line analysis graphing functions to allow users to compare and QC their sample standards. These advanced capabilities enable researchers to accommodate asymmetric data sets in their analysis. To streamline the development of new and existing assays, including IC-50 determination, enzymology, early ADME, nucleic acids, and ELISA, users can select from 120 pre-developed assay protocols. With customizable analysis protocols, considerable time and cost is saved by not having to export raw data to Excel or other programs.

The SoftMax Pro 5 GxP edition was developed specifically for customers who are required to comply with multiple regulatory requirements. SoftMax Pro 5 GxP has networked-linked user management tools to allow companies to securely host and manage authorized researchers worldwide. The software will ship with complete validation tools to reduce cost and validation time.

Molecular Devices Corporation is a leading supplier of high-performance bioanalytical measurement systems that accelerate and improve drug discovery and other life sciences research. The Company's systems and consumables enable pharmaceutical and biotechnology companies to leverage advances in genomics, proteomics and parallel chemistry to facilitate the high-throughput and cost-effective identification and evaluation of drug candidates. The Company's solutions are based on its advanced core technologies that integrate its expertise in engineering, molecular and cell biology and chemistry. Molecular Devices enables its customers to improve research productivity and effectiveness, which ultimately accelerates the complex process of discovering and developing new drugs.

This press release contains 'forward-looking' statements, including statements related to the prospects for or potential customer use of the SoftMax Pro 5 software. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as 'believes,' 'anticipates,' 'plans,' 'expects,' 'will,' and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause the results of Molecular Devices Corporation to differ materially from those indicated by these forward-looking statements, including, among others, risks related to the development of new products and commercial acceptance, and other risks detailed from time to time in the Company's SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2005. Molecular Devices Corporation does not undertake any obligation to update forward-looking statements.

Molecular Devices Corporation

Softmax Pro 5 Software Full Version

Softmax Pro 5 Software Free

CONTACT: Tim Harkness of Molecular Devices Corporation, +1-408-747-3533